CN103288922A - Tumor necrosis factor (TNF)-alpha polypeptide inhibitor and application thereof - Google Patents
Tumor necrosis factor (TNF)-alpha polypeptide inhibitor and application thereof Download PDFInfo
- Publication number
- CN103288922A CN103288922A CN2013102090915A CN201310209091A CN103288922A CN 103288922 A CN103288922 A CN 103288922A CN 2013102090915 A CN2013102090915 A CN 2013102090915A CN 201310209091 A CN201310209091 A CN 201310209091A CN 103288922 A CN103288922 A CN 103288922A
- Authority
- CN
- China
- Prior art keywords
- tumor necrosis
- necrosis factor
- peptide inhibitor
- alpha
- tnf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention provides a tumor necrosis factor (TNF)-alpha polypeptide inhibitor and application thereof and relates to the field of drugs and in particular relates to a polypeptide which has the function of inhibiting TNF-alpha and can prevent and treat rheumatoid arthritis (RA). The sequence of the polypeptide is Asp-Thr-Tyr-His-Ser and is a brand new sequence. The inhibitor has the beneficial effects that the inhibitor can be used for treating RA and has potential new drug development value.
Description
Technical field:
The present invention relates to pharmaceutical field, be specifically related to the tumor necrosis factor-alpha peptide inhibitor for prevention and treatment or prevention rheumatoid arthritis.
Background technology:
(rheumatoid arthritis RA) is one of clinical modal inflammatory arthropathy and main disability-causing factor to rheumatoid arthritis.Be about 0.5%-1.0% in the whole world, the morbidity of RA is about 0.4% in China.RA can betide any age, and with advancing age, sickness rate also increases thereupon.The women is 45-55 year at the age occurred frequently, and sex and RA onset relation are close, the men and women than about 1:3.RA is the chronic systemic inflammatory disease that a kind of cause of disease is not understood as yet, is main clinical manifestation with pathology outside chronic, symmetry, many synovial joints inflammation and the joint, belongs to the autoimmunization inflammatory diseases.The patient is first symptom with hand or wrist pain and swelling (the particularly swelling at wrist back) often, and symptom continues not alleviate, though common symptomatic treatment can relief of symptoms, usually irregularly or in shortage owing to medication causes symptom repeatedly.Can occur deadlock in tangible morning during disease progression, can reach more than 1 hour usually, and constantly increase the weight of; Certain joint function disturbance appears simultaneously.
The cause of disease of rheumatoid arthritis and pathogenesis are not clear fully as yet, and its basic pathology characteristics are vasculitis and synovitis.Intraarticular synovial membrane blood vessel hyperplasia forms pannus, causes synovial membrane to thicken, and oozes out and increases, and the secretion various kinds of cell factor is invaded cartilage and caused bone damage.Flesh chamber, ligament, stndon sheath and muscle etc. around it are organized also all erodables, thereby influence stablizing of joint, easily joint deformity takes place and dysfunction occurs.Vasculitis also can be invaded each organs and tissues of the whole body, forms systemic disease.
The medicine for the treatment of RA is divided into two big classes at present: control symptom medicine and control disease medicine.Because the RA etiology unknown can be rated as the medicine of controlling disease so there is no now.The antirheumatic of control symptom is divided into four classes: one, non-steroidal anti-inflammatory drugs, be commonly referred to a line medicine, and this class medicament categories is various, and the domestic market has reached tens of kinds.Two, steroid hormone, hormone are extraordinary pain stop and anti-inflammation medicines, but long-term use separately can not improve the state of an illness, bring many side effects on the contrary, hormone is made transitionality before the medication onset with being fine slowly as the two wires, but consumption is little, and the time is unsuitable long.Heavier in the state of an illness, with the patient of performance outside the joint, short impacts, and necessary during the medicine treatment of associating two wires.Three, act on antirheumatic slowly, be commonly referred to the two wires medicine, what is called acts on cartridge bag slowly and draws together antimalarial drug, golden salt, Trolovol and willow nitrogen sulfapyridine, and their treatment RA onsets are slow, and long term has certain mitigation to the RA state of an illness, so the feelings of also pretending illness are improved medicine.Four, immunosuppressor: using always has Rheumatrex, endoxan, azathioprine, trypterygine, Stem of Orientoine etc.
In the biotechnological formulation for the treatment of RA, studying maximum clinically is exactly the antagonist of tumor necrosis factor-alpha (TNF-α).TNF-α is one of important cytokine in active period RA synovial membrane and the blood, is mainly produced by the synovial membrane scavenger cell.It can stimulate the synovioblast hyperplasia, secretion IL-6, and granulocyte-macrophage colony stimutaing factor (GM-CSF), chemokine and effect molecules such as matrix metalloproteinase and prostaglandin(PG) play an important role in the morbidity of RA.The effect of TNF-alpha-2 antagonists is antagonism TNF-α specifically, suppresses the disease progression of RA.The TNF-alpha-2 antagonists of approved listing at present mainly contains etanercept (etanercept), Ying Fuli Xidan anti-(irdliximab) and adalimumab (adalimumab).Because these medicines are monoclonal antibody, it is bigger to exist molecular weight, reaches shortcomings such as producing antigen-reactive, has limited it greatly in clinical use.
Summary of the invention:
The present invention seeks to the characteristics at existing TNF-alpha-2 antagonists, design the little TNF-α polypeptide antagonist of a kind of molecular weight, can avoid producing antigen-reactive, be applicable to Clinical Application more.
Technical solution of the present invention provides a kind of tumor necrosis factor-alpha peptide inhibitor 3, and its sequence is Asp-Thr-Tyr-His-Ser, and the application in preparation treatment or prevention medicine for treating rheumatoid arthritis.
Principle of the present invention is that tumor necrosis factor-alpha is to be combined with Tumor Necrosis Factor Receptors with trimerical form, produce the effect of physiology or pathology, tumor necrosis factor-alpha peptide inhibitor 3 does not directly act on Tumor Necrosis Factor Receptors, but the trimerical formation of inhibition tumor necrosis factor-alpha, the effect of indirect inhibition Tumor Necrosis Factor Receptors, thus play the effect that prevents and treat rheumatoid arthritis.
Useful result:
Tumor necrosis factor-alpha peptide inhibitor 3 sequence A sp-Thr-Tyr-His-Ser among the present invention, can suppress tumor necrosis factor-alpha by target, suppress the physiology of Tumor Necrosis Factor Receptors generation or the effect of pathology, reach the effect of prevention or treatment rheumatoid arthritis.
The contriver knows that through a large amount of experiments tumor necrosis factor-alpha peptide inhibitor 3 can suppress the development of adjuvant type rat kind rheumatic arthritis and DBA/1 mouse collagen type rheumatoid arthritis, experimental results show that in the body and have the arthritic effect of significant treatment similar rheumatism type, and few side effects, the few cost of consumption reduces.Illustrate the present invention design tumor necrosis factor-alpha peptide inhibitor 3 science, reasonable, feasible effectively, can be as treatment or prevention medicine for treating rheumatoid arthritis.
Description of drawings:
Accompanying drawing 1 peptide inhibitor molecular configurations synoptic diagram.1.Asp aspartic acid, 2.Thr Threonine, 3.Tyr tyrosine, 4. His Histidine, 5. Ser Serine.
Embodiment
Embodiment 1
The chemical synthesis process of polypeptide
Polypeptide is synthetic with the Fmoc chemical process.Building-up reactions is carried out to the N end from the C end, and Rink medium (can buy in Advanced ChemTech company) has free amino group, the Ser that is linked in sequence, His, Tyr, Thr and Asp.In each step connection procedure, amino-acid residue all will activate, and the HBTU of 4 times of free amino groups on medium is arranged in the activator mixture, HOBt, DIEA and Fmoc-amino acid.After each amino acid whose ligation, all use the mixture of a pyridine/acetic acid/N-Methylimidazole (4:1:0.5) to seal the free amino group that does not connect, capping 10 min.After each amino acid whose ligation, next amino acid all will remove the Fmoc-group on the medium before connecting, and goes the Fmoc-group to use the dimethyl formamide that contains 20% piperidines, needs 15 minutes.At last, after all amino-acid residues were linked in sequence, polypeptide cut down from medium with 98% trifluoroacetic acid, and cutting was at room temperature carried out 2 hours.
Use above-mentioned electrochemical conditions and can synthesize and obtain polypeptide, sequence is Asp-Thr-Tyr-His-Ser, and this sequence is brand-new sequence.
Embodiment 2
Tumor necrosis factor-alpha peptide inhibitor 3 is immanoprotection action in collagen-induced mouse arthritis animal model
Make up collagen type mouse arthritis animal model, 3 pairs of collagen-induced property of mouse of research tumor necrosis factor-alpha peptide inhibitor sacroiliitis (collagen induced arthritis, therapeutic action CIA).Adopt mouse as animal subject, 90 of SPF level DBA/1 mouse (are provided by west, Shanghai pul-Bi Kai laboratory animal company limited (Sino-British SIPPR Lab. Animal Ltd), animal production licence number: SCXK (Shanghai) 2008-0016), male, age in 7-8 week, body weight is 18-22 g, be divided into 6 groups at random, it is respectively the normal control group, model control group, high 3 dosage groups (0.4,0.8,1.6 mg/kg) and positive drug control group (methotrexate 2 mg/kg) during peptide inhibitor 3 hangs down.Except normal group, each experimental group was set up mouse CIA model in the 0th day, and to be chicken cartilage II Collagen Type VI (c II) become the solution of 4 mg/ml with 0.1 mol/l acetate dissolution to method, in 4 ℃ of refrigerator overnight.Experiment was fully emulsified with complete Freund's adjuvant (CFA) equal-volume that contains 4 mg/ml Myeobaeterium tuberculosis strain H37Rv with the II Collagen Type VI same day, after treating the DBA/1 mouse anesthesia, 50 μ l carry out sensitization in every injection of its afterbody intracutaneous emulsifying agent, and the II Collagen Type VI (c II) with 4 mg/ml behind 21 d carries out immunity again with the fully emulsified back emulsifying agent with same dose of incomplete Freund's adjuvant (IFA) equal-volume in afterbody.Drug administration by injection under modeling the 30th d peeling: 3 dosage groups of polypeptide 3 (0.4,0.8,1.6 mg/kg): every day twice, continuous 10 days; Positive drug control group (methotrexate 2 mg/kg): per five days once, continuous 3 times; Normal control group and model control group (physiological saline): continuous 10 days.Respectively at weighing in the 21st day to the 70th day per 3 days after the modeling, the joint scoring, detecting left and right sides metapedes ankle diameter respectively and observe medicine to the arthritic influence of mouse collagen type.
The result: mouse is compared with normal mouse after the modeling, immunity back the 27th day, and CIA mouse foot pawl redness, the arthritis index scoring is increased, and model group 45-60 days was the swelling peak, and model group increases hardly from the 35th day beginning body weight, and the later stage also has decline slightly.Tumor necrosis factor-alpha peptide inhibitor 3 immanoprotection action concrete outcome in collagen-induced mouse arthritis animal model is as follows:
The influence of the whole pawl swelling degree in 3 pairs of mouse collagen types of tumor necrosis factor-alpha peptide inhibitor sacroiliitis left side, positive controls, the tumor necrosis factor-alpha peptide inhibitor left back ankle diameter of 3 high, medium and low dosage groups and model group relatively all have utmost point significant difference (P＜0.01) experimental result to have statistical significance.The influence of the right whole pawl swelling degree of 3 pairs of mouse collagen types of tumor necrosis factor-alpha peptide inhibitor sacroiliitis, positive controls, the tumor necrosis factor-alpha peptide inhibitor right back ankle diameter of 3 high, medium and low dosage groups and model group are relatively, utmost point significant difference (P＜0.01) is all arranged, and experimental result has statistical significance.The influence of 3 pairs of collagen type sacroiliitis of tumor necrosis factor-alpha peptide inhibitor mouse clinical score, polypeptide 3 basic, normal, high dosage group four limbs scorings significantly are lower than model control group (P＜0.01), compare utmost point significant difference with model control group, experimental result has statistical significance.The influence of 3 pairs of collagen type sacroiliitis of tumor necrosis factor-alpha peptide inhibitor mouse body weight, polypeptide 3 high, medium and low dosage group body weight are significantly higher than model control group (P＜0.01), compare utmost point significant difference with model control group, experimental result has statistical significance.
Conclusion: 3 pairs of mouse collagen types of tumor necrosis factor-alpha peptide inhibitor sacroiliitis has therapeutic action.
Embodiment 3
Immanoprotection action in 3 pairs of adjuvant types of tumor necrosis factor-alpha peptide inhibitor rat arthritis animal model
Make up adjuvant type rat arthritis animal model, 3 pairs of adjuvant-induced arthritises of research tumor necrosis factor-alpha peptide inhibitor (Adjuvant arthritis, AA) therapeutic action of rat.Adopt rat as animal subject, 90 of SPF level SD rats (are provided by west, Shanghai pul-Bi Kai laboratory animal company limited (Sino-British SIPPR Lab. Animal Ltd), animal production licence number: SCXK (Shanghai) 2008-0016), male, body weight is 140 g-160 g, be divided into 6 groups at random, it is respectively the normal control group, model control group, high 3 dosage groups (0.2 during tumor necrosis factor-alpha peptide inhibitor 3 hangs down, 0.4,0.8 mg/kg) and positive drug control group (methotrexate 1 mg/kg).Except normal group, each experimental group was set up rat AA model in the 0th day, and method is that mycobacterium tuberculosis (H37RA, 10 mg/ml) complete Freund's adjuvant 0.08 ml that injection contains deactivation that wastes time fully behind the left side of rat causes the rat assist agent arthritis model.Drug administration by injection under the 10th day peeling of modeling: 3 dosage groups of polypeptide 3 (0.2,0.4,0.8 mg/kg): every day twice, continuous 10 days; Positive drug control group (methotrexate 1 mg/kg): per five days once, continuous 3 times; Normal control group and model control group (physiological saline): continuous 10 days.Respectively at after the modeling the 8th, 11,14,17,20,23 and 26 days, weigh in, the joint scoring, detect left and right sides metapedes ankle diameter respectively and observe medicine to the arthritic influence of rat adjuvant type.
The result: rat is compared with normal rat after the modeling, and the left back foot of AA rat can produce primary sacroiliitis rapidly, tangible swelling occurs, and with festering; Begin to occur Secondary cases sacroiliitis behind about 10 d of right back foot, the score value of scoring increases gradually; Ear's blood vessel hyperplasia is obvious simultaneously, and is obviously red and swollen; Swelling appears in caudal articular process.Tumor necrosis factor-alpha peptide inhibitor 3 is immanoprotection action in adjuvanticity rat arthritis animal model, and concrete outcome is as follows:
The influence of 3 pairs of rat primary of tumor necrosis factor-alpha peptide inhibitor sacroiliitis foot pawl swelling degree, the left back ankle diameter of basic, normal, high dosage group of rat positive controls, tumor necrosis factor-alpha peptide inhibitor 3 and model group relatively have utmost point significant difference (P＜0.01); The tumor necrosis factor-alpha peptide inhibitor left back ankle diameter of 3 basic, normal, high dosage groups and model group relatively all have significant difference (P＜0.05), and experimental result has statistical significance.The influence of 3 pairs of rat Secondary cases of tumor necrosis factor-alpha peptide inhibitor sacroiliitis foot pawl swelling degree, rat positive controls, the tumor necrosis factor-alpha peptide inhibitor right back ankle diameter of 3 basic, normal, high dosage groups and model group relatively have significant difference (P＜0.05).Tumor necrosis factor-alpha peptide inhibitor 3 I are to the influence of adjuvant type rats with arthritis clinical score, and the scoring of the basic, normal, high dosage group of polypeptide I four limbs significantly is lower than model control group (P＜0.05), with the model control group comparing difference statistical significance is arranged all.The influence of 3 pairs of adjuvant types of tumor necrosis factor-alpha peptide inhibitor rats with arthritis body weight, polypeptide 3 high, medium and low dosage group body weight are significantly higher than model control group (P＜0.05), with the model control group comparing difference statistical significance are arranged all.
Conclusion: 3 pairs of AA rat arthritis of tumor necrosis factor-alpha peptide inhibitor have therapeutic action.
SEQUENCE LISTING
＜110〉Suzhou Pu Luoda bio tech ltd
＜120〉tumor necrosis factor-alpha peptide inhibitor 3 and application thereof
<130>
<160> 1
<170> Patent In version 3.3
<210> 1
<211> 5
<212> PRT
＜213〉artificial sequence
<400> 1
Asp Thr Tyr His Ser
1 5
Claims (2)
1. the tumor necrosis factor-alpha peptide inhibitor 3, it is characterized in that its sequence is Asp-Thr-Tyr-His-Ser.
2. the tumor necrosis factor-alpha peptide inhibitor 3, the application in preparation treatment or prevention medicine for treating rheumatoid arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102090915A CN103288922A (en) | 2013-05-30 | 2013-05-30 | Tumor necrosis factor (TNF)-alpha polypeptide inhibitor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102090915A CN103288922A (en) | 2013-05-30 | 2013-05-30 | Tumor necrosis factor (TNF)-alpha polypeptide inhibitor and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103288922A true CN103288922A (en) | 2013-09-11 |
Family
ID=49090497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102090915A Pending CN103288922A (en) | 2013-05-30 | 2013-05-30 | Tumor necrosis factor (TNF)-alpha polypeptide inhibitor and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103288922A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103739677A (en) * | 2013-12-31 | 2014-04-23 | 罗瑞雪 | Polypeptide capable of inhibiting nuclear factor-kappaB and application thereof |
-
2013
- 2013-05-30 CN CN2013102090915A patent/CN103288922A/en active Pending
Non-Patent Citations (5)
| Title |
|---|
| 孔纯玉等: "类风湿性关节炎的生物治疗 ", 《医学综述》 * |
| 孔纯玉等: "类风湿性关节炎的生物治疗", 《医学综述》, no. 12, 20 June 2007 (2007-06-20) * |
| 张志红等: "肿瘤坏死因子抑制剂治疗类风湿性关节炎的研究进展", 《中国药房》 * |
| 张文等: "肿瘤坏死因子抑制剂治疗类风湿关节炎 ", 《基础医学与临床》 * |
| 张文等: "肿瘤坏死因子抑制剂治疗类风湿关节炎", 《基础医学与临床》, no. 09, 20 September 2006 (2006-09-20) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103739677A (en) * | 2013-12-31 | 2014-04-23 | 罗瑞雪 | Polypeptide capable of inhibiting nuclear factor-kappaB and application thereof |
| CN103739677B (en) * | 2013-12-31 | 2015-09-09 | 河北万通金牛药业有限公司 | A kind of suppression nuclear Factor-Kappa B polypeptide and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | A critical role for interleukin-1β in the progression of autoimmune diseases | |
| CN103739670A (en) | Polyethylene glycol modified polypeptide for inhibiting tumor necrosis factor-alpha and application of polypeptide | |
| CN104127859A (en) | Application of polypeptides in preparation of medicament for treating or preventing rheumatoid arthritis | |
| ES2627933T3 (en) | Peptide and its use | |
| CN106539814A (en) | Interferon gene stimulatory protein(SP)（STING）Application of the agonist in the diseases such as resisting rheumatoid arthritis | |
| CN103285373A (en) | Preparation method and application of tumor necrosis factor (TNF)-alpha polypeptide inhibitor | |
| CN103254291B (en) | Tumor necrosis factor-alpha polypeptide inhibitors and application thereof | |
| CN103265619A (en) | Tumor necrosis factor-alpha polypeptide inhibitor and application thereof | |
| CN103739669B (en) | A kind of suppression interleukin-6 polypeptide and application thereof | |
| CN103819540B (en) | Nf-KB peptide inhibitor and application thereof | |
| CN103772491B (en) | Nf-KB peptide inhibitor 3 and application thereof | |
| CN103772489B (en) | Nf-KB peptide inhibitor 5 and application thereof | |
| CN103739671B (en) | A kind of polyethyleneglycol modified suppression nuclear Factor-Kappa B polypeptide and application thereof | |
| CN103288922A (en) | Tumor necrosis factor (TNF)-alpha polypeptide inhibitor and application thereof | |
| CN103288921A (en) | Polypeptide inhibitor of vascular endothelial growth factor 2 tyrosine kinase and application thereof | |
| CN103739673B (en) | A kind of polyethyleneglycol modified suppression interleukin-6 polypeptide and application thereof | |
| CN103772492B (en) | Nf-KB peptide inhibitor 4 and application thereof | |
| CN101954072A (en) | Use of ulinastatin in preparation of drugs for treating rheumatoid arthritis and pharmaceutical composition thereof | |
| CN103739677B (en) | A kind of suppression nuclear Factor-Kappa B polypeptide and application thereof | |
| CN103923185A (en) | Interleukin-6 polypeptide inhibitor and its application | |
| CN103923180A (en) | Interleukin-6 polypeptide inhibitor and its application | |
| CN103923182A (en) | Interleukin-6 polypeptide inhibitor and its application | |
| CN103923183A (en) | Interleukin-6 polypeptide inhibitor and its application | |
| CN105061583A (en) | Peripheral interleukin 35 polypeptide and application thereof | |
| CN103254292A (en) | Tyrosine kinase tyrosine polypeptideinhibitor of vascular endothelial growth factor receptor 2 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130911 |